Alphamab Oncology

HK$6.25As of Sun 8 Nov 2026, 12:00 UTC
HKEX:9966Healthcare
Country Hong Kong
PE (Fwd) •••
TSR 7Y CAGR (11.09%)
Div yield —
ROE (9.98%)
Biotechnology
Beta (5Y) 0.67
PE TTM —
TSR TTM (45.61%)
Mkt cap HK$6.058B
ROIC (6.08%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$6.00
(4.14%)
(85.27%)
Hold 12|7|10|0|7
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
0.10
0.11
0.11
0.12
7.08%
17.16%
26.64%
22.14%
Revenue¥M
510.3
506.3
497.6
500.2
6.81%
3.55%
(2.09%)
1.36%
Peers (US$772.7M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
1.161
—
(0.011)
EBIT/Intx
0.474
0.144
0.148
Own earn%
133.81
17.84
19.80
Sh yield%
36.10
46.37
44.10
Owners
Insiders/Inst%
8.37
84.68
Short interest%
2.21
SBC / revenue%
3.20
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
16
Op margin range%
5–9
$1 testx
−0.1
Incr. ROIC%
4